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Abstract—Adverse drug reaction (ADR) is widely concerned 
for public health issue. In this study we propose an original 
approach to detect the ADRs using feature matrix and feature 
selection. The experiments are carried out on the drug Aspirin. 
Major side effects for the drug are detected and better 
performance is achieved compared to other computerized 
methods. The detected ADRs are based on the computerized 
method, further investigation is needed. 
I. INTRODUCTION 
ADVERSE drug reaction (ADR) is widely concerned for 
public health issue. ADRs are one of most common causes 
to withdraw some drugs from market [1]. Now two major 
methods for detecting ADRs are spontaneous reporting 
system (SRS) [2], [3], and prescription event monitoring 
(PEM)[4],[5]. The World Health Organization (WHO) 
defines a signal in pharmacovigilance as "any reported 
information on a possible causal relationship between an 
adverse event and a drug, the relationship being unknown or 
incompletely documented previously" [6]. For spontaneous 
reporting system, many machine learning methods are used 
to detect ADRs, such as Bayesian confidence propagation 
neural network (BCPNN) [7], decision support method [8], 
genetic algorithm [9], knowledge based approach [10], etc. 
One limitation is the reporting mechanism to submit ADR 
reports, which has serious underreporting and is not able to 
accurately quantify the corresponding risk. Another 
limitation is hard to detect ADRs with small number of 
occurrences of each drug-event association in the database. 
In this paper we propose feature selection approach to 
detect ADRs from The Health Improvement Network 
(THIN) database. First feature matrix, which represents the 
medical events for the patients before and after taking drugs, 
is created by linking patients' prescriptions and 
corresponding medical events together. Then significant 
features are selected based on feature selection methods, 
comparing the feature matrix before patients take drugs with 
one after patients take drugs. Finally the significant ADRs 
can be detected from thousands of medical events based on 
corresponding features. Experiments are carried out on the 
drug Aspirin. Good performance is achieved. 
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II. FEATURE MATRIX AND FEATURE SELECTION 
A. The Extraction Of Feature Matrix 
To detect the ADRs of drugs, first feature matrix is 
extracted from THIN database, which describes the medical 
events that patients occur before or after taking drugs. Then 
feature selection method of Student's t-test is performed to 
select the significant features from feature matrix containing 
thousands of medical events. Figure 1 shows the process to 
detect the ADRs using feature matrix. Feature matrix A 
describes the medical events for each patient during 60 days 
before they take drugs. Feature matrix B reflects the 
medical events during 60 days after patients take drugs. In 
order to reduce the effect of the small events, and save the 
computation time and space, we set 100 patients as a group. 
Matrix X and Y are feature matrix after patients are divided 
into groups. 
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Fig. 1. The process to detect ADRs. Matrix A and B are feature 
matrix before patients take drugs or after patients take drugs. The time 
period of observation is set to 60 days. Matrix X and Y are feature 
matrix after patients are divided into groups. We set 100 patients as one 
group. 
B. Medical Events And Readcodes 
Medical events or symptoms are represented by medical 
codes or Readcodes. There are 103387 types of medical 
events in "Readcodes" database. The Read Codes used in 
general practice (GP), were invented and developed by Dr 
James Read in 1982. The NHS (National Health Service) has 
expanded the codes to cover all areas of clinical practice. The 
code is hierarchical from left to right or from level 1 to level 
5. It means that it gives more detailed information from level 
1 to level 5. Table 1 shows the medical symptoms based on 
Readcodes at level 3 and at level 5. 'Other soft tissue 
disorders' is general term using Readcodes at level 3. 'Foot 
pain', 'Heel pain', etc., give more details using Readcodes at 
level 5. 
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C. Feature Selection Based On Student's t-test 
Feature extraction and feature selection are widely used in 
biomedical data processing [11]-[18]. In our research we 
use feature selection method of Student's t-test [19] to 
detect the significant ADRs from thousands of medical 
events. Student's t-test is a kind of statistical hypothesis test 
based on a normal distribution, and is used to measure the 
difference between two kinds of samples. 
TABLE I. 
MEDICAL EVENTS BASED ON READCODES AT LEVEL 3 AND LEVEL 5. 
Level Readcodes Medical events 
Muscle Level 3 N24..00 Other soft tissue disorders 
pain N245.16 Leg pain 
N245111 Toe pain 
Level 5 N245.13 Foot pain 
N245700 Shoulder pain 
N245.15 Heel pain 
D. Other Parameters 
The variable of ratio R, is defined to evaluate significant 
changes of the medical events, using ratio of the patient 
number after taking the drug to one before taking the drug. 
The variable R2 represents the ratio of patient number after 
taking the drug to the number of whole population having 
one particular medical symptom. 
The ratio variables R1 and R2 are defined as follows: 
R1 =
N/ 
B if NB#0; 
    NA  if NB=0; 
R2 =100 * NA I N 
where NB and NA represent the numbers of patients 
before or after they take drugs for having one particular 
medical event respectively. The variable N represents the 
number of whole population who take drugs. 
III. EXPERIMENTS AND RESULTS 
Drugs.com provides the side effects of Aspirin in [20], 
[21], including gastrointestinal, renal, hematologic, 
hypersensitivity, dermatologic, hepatic, oncologic, 
metabolic, cardiovascular, nervous system,  
musculoskeletal, respiratory, endocrine, ocular side effects. 
Some symptoms are heartburn, nausea, upset stomach, 
severe allergic reactions (rash; hives; itching; difficulty 
breathing; tightness in the chest; swelling of the mouth, 
face, lips, or tongue), black or bloody stools, confusion, 
diarrhea, dizziness, drowsiness, hearing loss, ringing in the 
ears, severe or persistent stomach pain, unusual bruising, 
vomiting, etc. 
17125 patients are taking Aspirin (ASPIRIN disp tab 
75mg, and 300mg) from 20GPs data in THIN database, 
removing the patients registered in GP less than 12 months. 
Based on Readcodes at level 1-5, totally 14546 medical 
events are obtained before or after patients take the drug. So 
17125x14546 feature matrix is obtained. Based on 
Readcodes at level 1-3, we combine the medical events, 
which have the same first three codes, into one medical 
event. Totally 2853 medical events are obtained, and  
17125x2853 feature matrix are created. After grouping them, 
171x14546 and 171x2853 feature matrix are formed to select 
the significant features, which reflect the significant change 
of medical events. 
Table 2 shows the top detected results in ascending order of 
p value of Student's t-test, using Readcodes at level 1-5 and 
at level 1-3. The detected results are using p value less than 
0.05, which represent the significant change after patients 
take the drug. Table 3 shows the results in descending order 
of the ratio of the number of patients after taking the drug to 
one before taking the drug. Table 4 shows potential ADRs 
related to cancer for Aspirin based on p value of Student's t-
test. The detected ADRs are based on the computerized 
method, further investigation is needed. 
IV. CONCLUSIONS 
In this study we propose a novel method to successfully 
detect the ADRs using feature matrix and feature selection. 
A feature matrix, which characterizes the medical events 
before patients take drugs or after patients take drugs, is 
created from THIN database. The feature selection method 
of Student's t-test is used to detect the significant features 
from thousands of medical events. The significant ADRs, 
which are corresponding to significant features, are 
detected. Experiments are performed on the drug Aspirin. 
The detected ADRs are based on the computerized method, 
further investigation is needed. 
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TABLE II THE TOP POTENTIAL ADRS FOR ASPIRIN BASED ON PVALUE OF STUDENT'S T-TEST. 
 Rank Readcodes Medical events NB NA R1 R2 
 1 1Z12.00 Chronic kidney disease stage 3 177 1169 6.60 6.83 
 2 M03z000 Cellulitis NOS 178 711 3.99 4.15 
 3 F4C0.00 Acute conjunctivitis 200 702 3.51 4.10 
 4 H06z000 Chest infection NOS 339 1392 4.11 8.13 
 5 N131.00 Cervicalgia - pain in neck 206 660 3.20 3.85 
Level 6 K197.00 Haematuria 55 304 5.53 1.78 
1-5 7 N143.00 Sciatica 126 409 3.25 2.39 
 8 K190.00 Urinary tract infection, site not specified 298 1010 3.39 5.90 
 9 F46..00 Cataract 115 475 4.13 2.77 
 10 C34..00 Gout 134 421 3.14 2.46 
 11 1M10.00 Knee pain 225 752 3.34 4.39 
 12 1992.00 Vomiting 87 419 4.82 2.45 
 13 H060.00 Acute bronchitis 222 791 3.56 4.62 
 14 N245.17 Shoulder pain 212 710 3.35 4.15 
 15 M0...00 Skin and subcutaneous tissue infections 63 287 4.56 1.68 
 16 D00..00 Iron deficiency anaemias 55 273 4.96 1.59 
 17 F45..00 Glaucoma 64 236 3.69 1.38 
 18 F4D0.00 Blepharitis 59 249 4.22 1.45 
 19 F501.00 Infective otitis externa 105 357 3.40 2.08 
 20 J510.00 Diverticulosis 38 195 5.13 1.14 
 1 1Z1..00 Chronic renal impairment 206 1389 6.74 8.11 
 2 H06..00 Acute bronchitis and bronchiolitis 944 2930 3.10 17.11 
Level 3 19F..00 Diarrhoea symptoms 290 1069 3.69 6.24 
1-3 4 M03..00 Other cellulitis and abscess 267 960 3.60 5.61 
 5 J57..00 Other disorders of intestine 115 465 4.04 2.72 
 6 171..00 Cough 842 2548 3.03 14.88 
 7 K19..00 Other urethral and urinary tract disorders 453 1584 3.50 9.25 
 8 N24..00 Other soft tissue disorders 1044 2863 2.74 16.72 
 9 H05..00 Other acute upper respiratory infections 331 1236 3.73 7.22 
 10 M22..00 Other dermatoses 248 802 3.23 4.68 
 11 N21..00 Peripheral enthesopathies and allied syndromes 324 1016 3.14 5.93 
 12 F4C..00 Disorders of conjunctiva 291 971 3.34 5.67 
 13 183..00 Oedema 337 1187 3.52 6.93 
 14 F46..00 Cataract 148 638 4.31 3.73 
 15 199..00 Vomiting 111 517 4.66 3.02 
 16 1D1..00 C/O: a general symptom 424 1461 3.45 8.53 
 17 1B8..00 Eye symptoms 255 832 3.26 4.86 
 18 D00..00 Iron deficiency anaemias 103 433 4.20 2.53 
 19 N13..00 Other cervical disorders 226 711 3.15 4.15 
 20 173..00 Breathlessness 761 1826 2.40 10.66 
 21 N09..00 Other and unspecified joint disorders 585 1675 2.86 9.78 
 22 1B1..00 General nervous symptoms 645 1675 2.60 9.78 
 23 B33..00 Other malignant neoplasm of skin 85 334 3.93 1.95 
 24 1C1..00 Hearing symptoms 177 566 3.20 3.31 
 25 1M1..00 Pain in lower limb 257 826 3.21 4.82 
 26 F59..00 Hearing loss 115 446 3.88 2.60 
 27 J10..00 Diseases of oesophagus 205 653 3.19 3.81 
 28 19C..00 Constipation 311 1067 3.43 6.23 
 29 J51..00 Diverticula of intestine 101 388 3.84 2.27 
 30 16C..00 Backache symptom 410 1331 3.25 7.77  
TABLE III. THE TOP POTENTIAL ADRS FOR ASPIRIN BASED ON DESCENDING ORDER OF R1 VALUE. 
Rank Readcodes Medical events NB NA R1 R2 
1 1Z1E.00 Chronic kidney disease stage 3A without proteinuria 0 38 38.00 0.22 
2 F4F2.00 Epiphora 1 30 30.00 0.18 
3 F591.00 Sensorineural hearing loss 1 27 27.00 0.16 
4 SK16000 Other hip injuries 1 22 22.00 0.13 
5 1A45.12 Haematuria - symptom 1 20 20.00 0.12 
6 F4A0.00 Corneal ulcer 0 19 19.00 0.11 
7 16J5.00 Facial swelling 1 19 19.00 0.11 
8 M12..12 Contact eczema 0 18 18.00 0.11  
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9 196B.00 Painful rectal bleeding 1 18 18.00 0.11 
10 G835.00 Infected varicose ulcer 1 17 17.00 0.10 
Level 11 199..00 Vomiting 1 17 17.00 0.10 
1-5 12 B33..00 Other malignant neoplasm of skin 2 32 16.00 0.19 
13 K241400 Acute epididymitis 1 16 16.00 0.09 
14 M07z200 Infection finger 1 16 16.00 0.09 
15 K08..00 Impaired renal function disorder 0 16 16.00 0.09 
16 G311400 Worsening angina 1 16 16.00 0.09 
17 1Z1G.00 Chronic kidney disease stage 3B without proteinuria 0 16 16.00 0.09 
18 F4Kz411 Red eye NOS 0 16 16.00 0.09 
19 Eu32z00 [X]Depressive episode, unspecified 0 16 16.00 0.09 
20 K120.12 Renal calculus 1 15 15.00 0.09 
1 J05..00 Other dental disease/condition of teeth/supporting structure 1 18 18.00 0.11 
2 E13..00 Other nonorganic psychoses 1 16 16.00 0.09 
3 F5...00 Diseases of the ear and mastoid process 0 16 16.00 0.09 
4 K13..00 Other kidney and ureter disorders 1 16 16.00 0.09 
5 1P5..00 Aggressive behaviour 1 14 14.00 0.08 
6 SA3..00 Open wound of toe(s) 1 14 14.00 0.08 
7 S83..00 Other open wound of head 2 26 13.00 0.15 
Level 8 F4A..00 Keratitis 4 48 12.00 0.28 
1-3 9 G72..00 Other aneurysm 0 12 12.00 0.07 
10 SH9..00 Bum - unspecified 0 12 12.00 0.07 
11 S60..00 Concussion 1 12 12.00 0.07 
12 K....00 Genitourinary system diseases 0 12 12.00 0.07 
13 C2...00 Nutritional deficiencies 1 12 12.00 0.07 
14 B....00 Neoplasms 0 11 11.00 0.06 
15 157..00 H/O: menstrual disorder 0 11 11.00 0.06 
16 K30..00 Benign mammary dysplasia 1 11 11.00 0.06 
17 1A6..00 Urethral discharge symptom 1 11 11.00 0.06 
18 J11..00 Gastric ulcer - (GU) 7 74 10.57 0.43 
19 K08..00 Impaired renal function disorder 2 21 10.50 0.12 
20 J67..00 Diseases of pancreas 4 40 10.00 0.23 
TABLE IV. THE POTENTIAL ADRS RELATED TO CANCER FOR ASPIRIN BASED ON PVALUE OF STUDENT'S T-TEST. 
Rank Readcodes Medical events NB NA R1 R2  
1 B33..00 Other malignant neoplasm of skin 85 334 3.93 1.95 
2 B76..00 Benign neoplasm of skin 76 224 2.95 1.31 
3 B34..00 Malignant neoplasm of female breast 19 99 5.21 0.58 
4 B22..00 Malignant neoplasm of trachea, bronchus and lung 14 80 5.71 0.47 
5 B46..00 Malignant neoplasm of prostate 57 163 2.86 0.95 
6 BB2..00 [M]Papillary and squamous cell neoplasms 15 86 5.73 0.50 
7 B8...00 Carcinoma in situ 16 58 3.63 0.34 
8 B13..00 Malignant neoplasm of colon 12 45 3.75 0.26 
9 B32..00 Malignant melanoma of skin 4 29 7.25 0.17 
10 1J0..00 Suspected malignancy 11 51 4.64 0.30 
11 B14..00 Malignant neoplasm of rectum, rectosigmoid junction and anus 5 31 6.20 0.18 
12 BB3..00 [M]Basal cell neoplasms 7 37 5.29 0.22 
13 B49..00 Malignant neoplasm of urinary bladder 8 31 3.88 0.18 
14 B10..00 Malignant neoplasm of oesophagus 4 22 5.50 0.13 
15 B59..00 Malignant neoplasm of unspecified site 3 26 8.67 0.15 
16 BB5..00 [M]Adenomas and adenocarcinomas 19 54 2.84 0.32 
17 B17..00 Malignant neoplasm of pancreas 3 19 6.33 0.11 
18 B7F..00 Benign neoplasm of brain and other parts of nervous system 0 10 10.00 0.06 
19 B58..00 Secondary malignant neoplasm of other specified sites 3 18 6.00 0.11 
20 B43..00 Malignant neoplasm of body of uterus 2 15 7.50 0.09 
21 B57..00 Secondary malig neop of respiratory and digestive systems 3 17 5.67 0.10 
22 B81..00 Carcinoma in situ of respiratory system 1 10 10.00 0.06 
23 B82..00 Carcinoma in situ of skin 0 7 7.00 0.04 
24 BB4..00 [M]Transitional cell papillomas and carcinomas 6 19 3.17 0.11 
25 B44..00 Malignant neoplasm of ovary and other uterine adnexa 2 10 5.00 0.06 
26 B83..00 Carcinoma in situ of breast and genitourinary system 15 32 2.13 0.19 
27 B80..00 Carcinoma in situ of digestive organs 3 11 3.67 0.06 
28 B51..00 Malignant neoplasm of brain 1 7 7.00 0.04 
29 B11..00 Malignant neoplasm of stomach 5 14 2.80 0.08 
30 BBG..00 [M]Fibromatous neoplasms 0 4 4.00 0.02 
 
